OPERON ELEVATEPLUS | US FDA 510(k) CONSULTING
FDA 510(k) Clearance & Submission Consulting
Take the next step
Operon ElevatePlus
US FDA 501(k) for Medical Devices Service Portfolio
Regulatory Strategy & Device Assessment
Analyze device classification and regulatory pathway suitability
Identify applicable FDA regulations for hardware, software, and IVDs
Define submission strategy aligned with FDA expectations
Documentation & 510(k) Submission Preparation
Compile complete FDA 510(k) technical dossier
Prepare substantial equivalence justification
Develop device description, labeling, and performance documentation
Predicate Identification & Substantial Equivalence Evaluation
Conduct in-depth predicate device research
Demonstrate intended use and technological equivalence
Align testing data and documentation with predicate requirements
FDA Registration for Software as a Medical Device (SaMD)
SaMD classification and regulatory pathway assessment
FDA 510(k) strategy for standalone software & AI/ML-based devices
Compliance with FDA software guidance, IEC 62304 & cybersecurity requirements
Preparation of software documentation (software description, architecture, validation & verification)
Support for FDA submission, queries, and clearance for SaMD products
FDA Submission & Communication Support
Submission of 510(k) application to the FDA
Monitoring submission status and FDA review cycles
Response to FDA questions, deficiencies, and additional information requests
QMS Alignment & Post-Submission Support
Alignment with FDA 21 CFR Part 820 Quality System Regulation
Support for post-clearance compliance and future submissions
Guidance for product changes, software updates, and lifecycle management
FDA for SiMD/SaMD
Software classification & FDA regulatory pathway assessment
510(k) strategy for SaMD and software-driven devices
Predicate identification & substantial equivalence analysis
FDA-compliant software documentation preparation
FDA registration, listing & lifecycle support
Understanding the requirement of Clinical study/Evidence for SaMD